Andrea T Wang

发表

Etanercept as monotherapy in patients with psoriasis.

A. Gottlieb, C. Leonardi, R. Zitnik, 2003, The New England journal of medicine.

Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial.

B. Elewski, K. Papp, R. Zitnik, 2006, Journal of the American Academy of Dermatology.

Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy

A. Gottlieb, B. Elewski, K. Gordon, 2006, The Journal of dermatological treatment.

Comparison of proximal femur and vertebral body strength improvements in the FREEDOM trial using an alternative finite element methodology.

H. Genant, P. Zysset, K. Engelke, 2015, Bone.

Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

Claus Christiansen, Cesar Libanati, Michael R McClung, 2009, The New England journal of medicine.

Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture

J. Adachi, E. Franek, M. McClung, 2012, Menopause.

Response to: Comment on: “Denosumab Rapidly Increases Cortical Bone in Key Locations of the Femur: A 3D Bone Mapping Study in Women With Osteoporosis”

Graham M. Treece, Jacques P. Brown, A. Gee, 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial.

S. Cummings, M. Bhandari, S. Boonen, 2012, The Journal of bone and joint surgery. American volume.

Reduction of Cortical Bone Turnover and Erosion Depth After 2 and 3 Years of Denosumab: Iliac Bone Histomorphometry in the FREEDOM Trial

D. Dempster, R. Chapurlat, P. Chavassieux, 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Response to Dr Lamy and Dr Gonzalez‐Rodriguez

Jacques P. Brown, S. Cummings, S. Ferrari, 2018, Journal of Bone and Mineral Research.

Effect of denosumab on fasting glucose in women with diabetes or prediabetes from the FREEDOM trial

E. Vittinghoff, A. Schwartz, N. Pannacciulli, 2018, Diabetes/metabolism research and reviews.

Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study

J. Adachi, S. Ferrari, Andrea T Wang, 2017, BMC Musculoskeletal Disorders.

Safety Observations With 3 Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab During the Randomized FREEDOM Trial and Subjects Who Crossed Over to Denosumab During the FREEDOM Extension

Jacques P. Brown, N. Watts, E. Lewiecki, 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis.

A. Nakanishi, I. Nestorov, R. Zitnik, 2006, British journal of clinical pharmacology.

Timing and durability of response to erenumab in patients with episodic migraine

U. Reuter, Andrea T Wang, P. McAllister, 2021, Headache.

Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions

S. Silberstein, M. Ashina, U. Reuter, 2019, Cephalalgia : an international journal of headache.

Two‐Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD

P. Miller, M. McClung, E. Lewiecki, 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial

A. Gottlieb, D. Cella, K. Papp, 2006, The Lancet.

Denosumab Rapidly Increases Cortical Bone in Key Locations of the Femur: A 3D Bone Mapping Study in Women With Osteoporosis

Andrew H Gee, Graham M Treece, Graham M. Treece, 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

RANKL Inhibition With Denosumab Does Not Influence 3‐Year Progression of Aortic Calcification or Incidence of Adverse Cardiovascular Events in Postmenopausal Women With Osteoporosis and High Cardiovascular Risk

D. Kiel, C. Christiansen, P. Miller, 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo‐Controlled FREEDOM Trial and Its Extension

Jacques P. Brown, S. Cummings, R. Eastell, 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis

S. Cummings, R. Rizzoli, S. Boonen, 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.

Jacques P. Brown, S. Cummings, J. Reginster, 2017, The lancet. Diabetes & endocrinology.

The Effect of Three or Six Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension

Jacques P. Brown, S. Cummings, E. Vittinghoff, 2013, The Journal of clinical endocrinology and metabolism.

Effects of denosumab on bone turnover markers in postmenopausal osteoporosis

S. Cummings, C. Christiansen, I. Reid, 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Bone‐Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment

Jacques P. Brown, A. Grauer, R. Chapurlat, 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX

J. Kanis, E. McCloskey, E. Siris, 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Denosumab significantly increases DXA BMD at both trabecular and cortical sites: results from the FREEDOM study.

M. Brandi, P. Lakatos, A. Høiseth, 2011, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Discontinuation of Denosumab and Associated Fracture Incidence: Analysis From the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial

Jacques P. Brown, A. Grauer, C. Roux, 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Denosumab Reduces Cortical Porosity of the Proximal Femoral Shaft in Postmenopausal Women With Osteoporosis

A. Høiseth, J. Zanchetta, M. McClung, 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study.

P. Geusens, W. Lems, K. Saag, 2018, The lancet. Diabetes & endocrinology.

Further Nonvertebral Fracture Reduction Beyond 3 Years for up to 10 Years of Denosumab Treatment.

P. Miller, C. Roux, E. Lewiecki, 2019, The Journal of clinical endocrinology and metabolism.

Continuance on etanercept after early incomplete response in patients with psoriasis

M. Lebwohl, R. Zitnik, G. Krueger, 2004 .

Withdrawal from etanercept after successful clinical response in psoriasis patients: disease characteristics and the durability of treatment response

A. Gottlieb, K. Gordon, R. Zitnik, 2004 .

Timing and durability of response to erenumab in patients with chronic migraine

M. Ashina, S. Tepper, T. Schwedt, 2021, Headache.

Denosumab densitometric changes assessed by quantitative computed tomography at the spine and hip in postmenopausal women with osteoporosis.

Jacques P. Brown, M. Brandi, E. Franek, 2013, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk.

S. Cummings, O. Tørring, S. Boonen, 2011, The Journal of clinical endocrinology and metabolism.

Observations following discontinuation of long-term denosumab therapy

P. Miller, M. McClung, E. Lewiecki, 2017, Osteoporosis International.

Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis

M. Brandi, D. Hans, J. Zanchetta, 2017, Osteoporosis International.

Long‐term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis

M. Weatherall, M. Ashina, A. Gantenbein, 2022, Headache.

Denosumab in postmenopausal women with osteoporosis and diabetes: Subgroup analysis of FREEDOM and FREEDOM extension.

S. Cummings, R. Eastell, L. Hofbauer, 2020, Bone.

Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis

R. Rizzoli, J. Gallagher, J. Adachi, 2015, Climacteric : the journal of the International Menopause Society.

Denosumab densitometric changes assessed by quantitative computed tomography at the spine and hip in postmenopausal women with osteoporosis.

Jacques P. Brown, M. Brandi, E. Franek, 2013, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Fracture risk factors during treatment with denosumab

S. Cummings, E. Vittinghoff, L. Lui, 2013 .

Long‐term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis

S. Silberstein, D. Dodick, M. Ashina, 2023, Headache.

Effects of denosumab on bone turnover markers in postmenopausal osteoporosis

S. Cummings, C. Christiansen, I. Reid, 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis

S. Cummings, R. Rizzoli, S. Boonen, 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years

O. Tørring, J. Reginster, C. O’Malley, 2015, Osteoporosis International.